Related Experiment Video

Updated: Aug 16, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth

Tai-Lung Cha1, Lin Qiu, Chun-Te Chen

  • 1Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Cancer Research
|March 23, 2005
PubMed

Insights

Emodin, a natural compound, effectively suppresses prostate cancer cell growth by targeting the androgen receptor (AR). This compound offers a promising therapeutic strategy for advanced prostate cancer, inhibiting AR activity and promoting its degradation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hormone-refractory relapse is a critical challenge in advanced prostate cancer.
  • Androgen receptor (AR) signaling is central to prostate cancer initiation and progression.
  • Targeting AR down-regulation is a key strategy for novel prostate cancer therapies.

Purpose of the Study:

  • To investigate the potential of emodin, a natural compound, as a therapeutic agent for prostate cancer.
  • To elucidate the mechanism by which emodin affects androgen receptor (AR) activity and prostate cancer cell growth.

Main Methods:

  • In vitro studies on prostate cancer cell lines.
  • In vivo studies using C3(1)/SV40 transgenic mice.
  • Analysis of AR nuclear translocation, AR-HSP90, and AR-MDM2 interactions.
  • Assessment of proteasome-mediated AR degradation.

Main Results:

  • Emodin directly targets the androgen receptor (AR), suppressing prostate cancer cell growth in vitro.
  • Emodin treatment prolonged survival in a mouse model of prostate cancer.
  • Emodin inhibited AR nuclear translocation and androgen-dependent transactivation.
  • Emodin promoted AR degradation via the proteasome pathway by altering AR-HSP90 and AR-MDM2 associations.

Conclusions:

  • Emodin demonstrates anticancer effects by directly targeting and degrading the androgen receptor (AR) in a ligand-independent manner.
  • The findings reveal a novel mechanism for emodin's anticancer activity.
  • Emodin warrants further investigation as a potential therapeutic and preventive agent for prostate cancer.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 19, 2013

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...